Get started
Author

Rubin Lubomirov

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
2009 · Julia di Iulio, Aurélie Fayet, et al. · Pharmacogenetics and Genomics · 153
Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals
2009 · M Arab-Alameddine, J Di Iulio, et al. · Clinical Pharmacology & Therapeutics · 129
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir
2010 · Rubin Lubomirov, Julia di Iulio, et al. · Pharmacogenetics and Genomics · 117
Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study
2010 · Rubin Lubomirov, Sara Colombo, et al. · The Journal of Infectious Diseases · 101
PDF
Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons
2013 · Margalida Rotger, Tracy R. Glass, et al. · Clinical Infectious Diseases · 77
PDF
An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease
2012 · Alberto M. Borobia, Rubin Lubomirov, et al. · PLoS ONE · 69
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
2022 · Jose F Varona, Pedro Landete, et al. · Life Science Alliance · 61
PDF
Phase 1 study of two inodilators in neonates undergoing cardiovascular surgery
2012 · Adelina Pellicer, Joan Riera, et al. · Pediatric Research · 57
Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals
2012 · Mona Arab-Alameddine, Aurélie Fayet-Mello, et al. · Antimicrobial Agents and Chemotherapy · 48
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study
2012 · Maria Dobrinas, Séverine Crettol, et al. · Pharmacogenetics and Genomics · 45
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals
2014 · M. Arab-Alameddine, R. Lubomirov, et al. · Journal of Antimicrobial Chemotherapy · 33
PDF
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals
2012 · Rubin Lubomirov, Mona Arab-Alameddine, et al. · Pharmacogenetics and Genomics · 30
Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer
2018 · Carlos Fernandez-Teruel, Ignacio Gonzalez, et al. · Clinical Pharmacokinetics · 26
A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population
2016 · Hoi Y. Tong, Cristina Lucía Dávila-Fajardo, et al. · PLoS ONE · 23
ADME Pathway Approach for Pharmacogenetic Studies of Anti-HIV Therapy
2007 · Rubin Lubomirov, Chantal Csajka, et al. · Pharmacogenomics · 20
Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects
2018 · Dora Koller, Carmen Belmonte, et al. · Journal of Psychopharmacology · 17
PDF
Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics
2022 · Salvador Fudio, Alvaro Sellers, et al. · Cancer Chemotherapy and Pharmacology · 15
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.
2017 · Anaïs Glatard, Maria Dobrinas, et al. · Experimental and Clinical Psychopharmacology · 15
PDF
Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant
2017 · G N Almeida-Paulo, I Dapía García, et al. · The Pharmacogenomics Journal · 15
Limited sampling strategies for tacrolimus exposure (AUC0-24) prediction after Prograf®and Advagraf®administration in children and adolescents with liver or kidney transplants
2014 · Gonzalo N. Almeida-Paulo, Rubin Lubomirov, et al. · Transplant International · 11
Integrated exposure–response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
2021 · Carlos Fernández-Teruel, Salvador Fudio, et al. · Cancer Chemotherapy and Pharmacology · 10
PDF
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine
2018 · L. van Andel, H. Rosing, et al. · Journal of Pharmaceutical and Biomedical Analysis · 9
PDF
Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients
2022 · P. Aviles, R. Altares, et al. · Drug Metabolism and Disposition · 8
PDF
Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers
2010 · Paloma Oliver, Rubin Lubomirov, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 8
Population Pharmacokinetic‐Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin
2021 · Carlos Fernández‐Teruel, Rubin Lubomirov, et al. · The Journal of Clinical Pharmacology · 6
Works count: 52
Citation count: 1,153
H-index: 16
I10-index: 21
Year
Topic
Type